CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cervical and endometrial cancers.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with cervical and endometrial cancers.
  
  LEARNING OBJECTIVES

  • Understand the importance of microsatellite instability (MSI) and mismatch repair (MMR) assessment in endometrial cancer (EC), and adapt current testing practices to optimally identify patients with MSI-high or MMR-deficient disease.
  • Recognize the benefits observed with anti-PD-1/PD-L1 antibodies as monotherapy for MSI-high or MMR-deficient EC, and integrate these agents into patient care.
  • Appreciate available research findings with anti-PD-1/PD-L1 antibodies and chemotherapy as first-line treatment for advanced or recurrent EC, and consider the potential role of this strategy in the care of patients with MSI-high/MMR-deficient and MMR-proficient disease.
  • Review the biologic rationale for combining anti-PD-1/PD-L1 antibodies with agents targeting the VEGF pathway, and counsel patients about the effectiveness of this novel strategy for advanced EC that is not MSI high or MMR deficient.
  • Evaluate the efficacy and safety of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with platinum-based chemotherapy for metastatic cervical cancer (CC), and educate patients about the benefits and risks of these approaches.
  • Describe the scientific justification for, published data with and toxicity profiles of agents and strategies under investigation for EC or CC, and use this information to discuss clinical trial opportunities for patients.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  This educational activity for 1.75 contact hours is provided by RTP during the period of May 2023 to May 2024.
  
  This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/Meetings/ONS2023/Cervical-Endometrial/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  FOR SUCCESSFUL COMPLETION
  To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONS2023Cervical/Endometrial/NCPD.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY —The following faculty reported relevant financial relationships with ineligible entities:
  
  Paula J Anastasia, MN, RN, AOCN
  GYN Oncology Patient-Nurse Educator
  Los Angeles, California
  
  Advisory Committee: Merck; Speakers Bureau: Seagen Inc.
  
  Michael J Birrer, MD, PhD
  Vice Chancellor, UAMS
  Director, Winthrop P Rockefeller Cancer Institute
  Director, Cancer Service Line
  Professor of Biochemistry and Molecular Biology
  Director’s Endowed Chair for the Winthrop P Rockefeller Cancer Institute
  University of Arkansas for Medical Sciences
  Little Rock, Arkansas
  
  Advisory Board: AstraZeneca Pharmaceuticals LP, GSK, Mersana Therapeutics Inc.
  
  Jennifer Filipi, MSN, NP
  Department of Gynecologic Oncology
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  No relevant conflicts of interest to disclose.
  
  Brian M Slomovitz, MD
  Professor, OB-GYN, Florida International University
  Director, Gynecologic Oncology
  Co-Chair, Cancer Research Committee
  Mount Sinai Medical Center
  Miami, Florida
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, EQRx, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Incyte Corporation, Lilly, Merck, Novartis, Seagen Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from GSK and Karyopharm Therapeutics.
  
  Release date: May 2023
  Expiration date: May 2024
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.